Nikhil Prasad Fact checked by:Thailand Medical News Team Dec 03, 2024 1 day, 8 hours, 34 minutes ago
Medical News:
A Revolutionary Approach to COVID 19 Management
Recent research has unveiled a promising new application for calcium dobesilate, a drug traditionally used to manage vascular diseases. This retrospective study, conducted by researchers from the Mexican Council of Angiology, Virgen del Puerto Hospital, and Anáhuac University, explored the efficacy of calcium dobesilate (CaD) in addressing COVID-19 complications, specifically pulmonary vascular endotheliitis and thrombosis.
Researchers From Mexico Find That Calcium Dobesilate Helps in Treating COVID-19
Understanding the Study
The study analyzed data from 60 COVID-19 patients who were treated with calcium dobesilate (CaD) in addition to standard care. Conducted in outpatient clinics in Mexico City and Guadalajara, researchers examined patient demographics, medical history, symptoms, and treatment outcomes. Calcium dobesilate, administered at a median dose of 2 grams per day for an average duration of 28 days, was initiated about three days after diagnosis. This
Medical News report highlights the innovative potential of this treatment in improving clinical outcomes for COVID-19 patients.
Why Calcium Dobesilate
Calcium dobesilate is known for its angioprotective properties, commonly used in treating conditions like diabetic retinopathy. Its mechanism of action includes stabilizing the endothelial barrier, reducing inflammation, and mitigating vascular complications. In the context of COVID-19, where endothelial damage and coagulopathy are prominent, these properties make Calcium dobesilate a strong candidate for reducing disease severity.
Interestingly, Calcium dobesilate also interferes with the virus’s ability to enter human cells. SARS-CoV-2 utilizes heparan sulfate to bind to cell receptors and initiate infection. Studies show that Calcium dobesilate can stabilize heparan sulfate and prevent this interaction, reducing viral entry and potentially limiting disease progression.
Key Findings from the Study
The study presented compelling results:
-Clinical improvement was observed in 83% of patients within 18.6 days on average.
-Full recovery occurred in 70% of cases within 25.6 days.
-Only 8% of patients required hospitalization, with just one needing intubation.
-Notably, no deaths were reported among the participants.
Patients treated with Calcium dobesilate also demonstrated significant improvements in key laboratory markers such as D-dimer and ferritin levels, both of which are indicative of reduced inflammation and coagulation activity.
A Comprehensive Approach
The researchers highlighted that Calcium dobesilate complements standard COVID-19 therapies, including cor
ticosteroids and oxygen supplementation. Only 23% of patients required oxygen therapy, and 50% needed corticosteroids - a notable reduction compared to typical cases. By targeting endothelial dysfunction, Calcium dobesilate effectively reduces the cascading complications of COVID-19, such as severe respiratory failure and microvascular thrombosis.
Future Directions
While the findings are promising, the study authors urge caution. The research was limited by its retrospective design, small sample size, and lack of a control group. Further randomized, placebo-controlled trials are necessary to confirm these outcomes and establish Calcium dobesilate as a standard treatment for COVID-19-related complications.
Conclusions
Calcium dobesilate presents a transformative potential for managing COVID-19 complications. By addressing vascular endotheliitis and thrombosis, the drug not only improves survival rates but also enhances the quality of recovery for patients. Its dual action - protecting the vascular endothelium and reducing viral entry - positions it as a game-changer in the fight against the pandemic.
This study underscores the importance of innovative approaches in combating complex diseases. As the world continues to adapt to the challenges posed by COVID-19, treatments like Calcium dobesilate offer a beacon of hope for improved patient outcomes and healthcare resilience. With further validation, calcium dobesilate could become a cornerstone of COVID-19 management strategies.
The study findings were published on a preprint server and are currently being peer reviewed for publication into the journal: BMC Pulmonary Medicine.
https://www.researchsquare.com/article/rs-5227483/v1
For the latest COVID-19 News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/nad-metabolism-and-its-emerging-role-in-covid-19-treatment
https://www.thailandmedical.news/news/triazavirin-proves-effective-in-treating-covid-19
Share
Tweet
Share
